Trinity Biotech Announces Clinical Study Results Showing Next-Gen CGM+ Wearable Biosensor Platform Delivers Purpose-Built Capability To Iden

- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech’s CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - Demonstrates practical value of Trinity Biotech's proprietary multi-sensor wearable biosensor technology beyond glucose-only CGM monitoring - Reinforces differentiation opportunity for CGM+ within the $15 billion1 global CGM market DUBLIN and WILSONVILLE, Ore., July 02, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ: TRIB ), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced clinical study results demonstrating that its next-generation CGM+ wearable biosensor platform has successfully delivered a purpose-built capability to identify nocturnal compression-related false low glucose events, with its differentiated technology addressing a common limitation of conventional continuous glucose monitoring (CGM) systems.

These findings provide further validation of Trinity Biotech's multi-sensor CGM+ architecture and its ability to deliver valuable physiological context alongside glucose measurements.

The analysis utilized approximately 5,000 hours of device wear data collected from insulin-dependent people with diabetes during a pre-pivotal clinical trial completed during the second quarter of 2026.

By combining glucose measurements with additional physiological signals captured through a proprietary sensor architecture integrated within the CGM+ platform, Trinity Biotech developed an algorithm designed to distinguish false low glucose readings caused by sensor compression during sleep from true changes in blood glucose levels.

Compression-related false low glucose alarms are a common source of inaccurate CGM alerts.

Published academic research reports that compression lows can occur, on average, once every 5 to 6 days of CGM wear.2 These events can disrupt sleep, prompt unnecessary carbohydrate intake and, in automated insulin delivery systems, influence dosing decisions based on inaccurate glucose data.

In automated insulin delivery systems, a falsely low CGM reading may cause the pump to reduce or suspend insulin unnecessarily, potentially increasing the risk of later hyperglycaemia.

For users managing diabetes manually, false alarms can lead to unnecessary carbohydrate intake for a low glucose event that did not occur.

This may then require correction for elevated glucose, creating avoidable variability often described as "rollercoasting." Because compression lows most often occur overnight, they can also drive sleep disruption and alarm fatigue.

The study findings demonstrate how Trinity's groundbreaking multi-sensor approach can provide physiological context not available in conventional glucose-only CGM systems.

Management believes this capability is an important example of how CGM+ can deliver greater utility to users by addressing real-world pain points such as false alarms, sleep disruption and avoidable glucose variability, while also offering automated insulin delivery system providers richer, more contextual data that may support improved system accuracy and decision-making.

Trinity believes this dual value proposition can strengthen the differentiation, partner relevance and commercial opportunity for its CGM+ solution.